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Abstract
In recent years, the use of more sensitive diagnostic techniques has demonstrated a 
significant number of malaria infections at densities beneath the limit of detection of 
conventional microscopy and rapid diagnostic tests (RDT). These low-density infections 
are almost always asymptomatic, found in all endemic settings, including those nearing 
elimination, and in all ages of the population. They typically account for a high propor-
tion of all infections and since they have also been shown to be infectious to mosquitoes, 
low-density infections are thought to be important contributors to maintaining malaria 
transmission. However, there is currently no direct evidence that specifically targeting 
this low-density parasite reservoir will hasten progress towards elimination. In this 
chapter we review the data to date and identify knowledge gaps. We present potential 
scenarios for the causes of low-density infections, if and how these might drive transmis-
sion, and the likely impact of specifically targeting them.
Keywords: asymptomatic malaria, transmission, longitudinal carriage, malaria 
elimination, diagnostics
1. Epidemiology and relevance of asymptomatic infections
It has long been acknowledged that not all Plasmodium falciparum infections lead to clinical 
symptoms, and in the vast majority of malaria endemic settings most infections are asymp-
tomatic. In the last two decades data on infection prevalence in endemic populations have 
been generated using nucleic acid amplification techniques (NAAT). The use of these sensi-
tive diagnostic methods showed that, on average, there are approximately twice the number 
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of infections than those identified with more conventional diagnostics, such as microscopy 
[1] and rapid diagnostic tests (RDT) [2], with most of these previously undetected infections 
being asymptomatic. Indeed, the association between clinical disease and relatively high para-
site levels [3–5] implies that most asymptomatic infections are also low-density, although par-
asitaemias above the microscopy detection limit are common in seemingly healthy infected 
individuals in endemic areas [3]. Of particular relevance, in light of the renewed interest in 
malaria elimination, is that in areas with low levels of transmission, often a high proportion of 
infections detected during prevalence surveys have sub-patent parasite densities (below the 
detection threshold of conventional diagnostics) [1].
For malaria elimination, a major consideration is how much the following different types of 
infections contribution to onwards transmission to mosquitoes: (1) clinical symptomatic and 
patent, (2) asymptomatic and patent, (3) asymptomatic and sub-patent, and what are the rela-
tive proportions of these infections in different endemic settings. Broadly speaking, the proba-
bility of a mosquito becoming infected after feeding on an infected human is dependent on the 
density of gametocytes. At an individual level, this probability of infection is higher from those 
with higher density symptomatic infections than those individuals with low-density asymp-
tomatic infections [6], provided there has been enough time for gametocytes to fully mature 
(8–12 days). At a population level, contributions to malaria transmission from each of the three 
types of infections detailed above may be more balanced as there will be more individuals with 
low density infections than high density infections. In the context of control and elimination, 
symptomatic infections often have a very short duration because symptomatic individuals are 
more likely to seek and receive treatment and have their infections curtailed. This is more pro-
nounced if treatment is given early after establishment of blood stage infection as gametocytes 
will be at relatively low densities and may not reach highly infectious levels.
Much of the data on asymptomatic infections is from community cross-sectional surveys. 
However, these snapshots are less informative on the dynamics of parasitaemia over time in 
individual infections. For example, an individual with a sub-patent infection today has several 
different potential infection outcomes (Figure 1). S/he may have been recently infected and 
will develop patent infection and clinical symptoms shortly afterwards, or alternatively may 
become a chronic parasite carrier, remaining asymptomatic for weeks or months. Conversely, 
individuals with sub-patent infections identified in cross-sectional surveys may also be at the 
tail end of an infection and will only remain minimally infectious for a short period of time 
(Figure 1). The contributions to onwards transmission from sub-patent infections that are 
only briefly asymptomatic [7] (all symptomatic infections invariably have a pre-clinical incu-
bation period) and those that are chronic are likely to be very different. In community mass 
treatment campaigns that aim to interrupt transmission, clearing the infections of individuals 
who would otherwise go on develop symptoms, seek and obtain effective treatment a few 
days later, will reduce morbidity but is likely to have a smaller impact on reducing onwards 
transmission than treating infections in individuals who remain asymptomatic for several 
months. Estimations of the duration of malaria infections are necessary to understand the 
consequences of imperfect coverage during these interventions. However, quantifying infec-
tion duration in endemic settings is complicated because individuals are frequently super-
infected with different falciparum clones, which means that periods of continuous parasite 
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carriage often represent overlapping infections with different clones. A longitudinal study in 
Ghana using msp-2 genotyping to distinguish parasite strains showed that naturally occur-
ring infections last on average 5–6 months [8]. In Myanmar, in an area with transmission 
approaching elimination levels and consequently low probability of super-infection, falci-
parum carriage of at least 6–9 months was observed [9]. A study in Cambodia, which followed 
24 adults with asymptomatic falciparum infections monthly, found that 13% carried parasites 
for 2–4 months, whereas the remaining 87% had cleared their parasitaemia after 1 month [10]. 
Finally, in a recent cohort study in Vietnam, nearly 10% of infected individuals carried para-
sites for 4 months or longer [11]. These studies vary in design such that a mean duration is 
hard to estimate, however, the data demonstrate that chronic carriage occurs in a wide range 
of endemicities, although its frequency and duration is likely context-specific.
Identifying the factors that moderate parasite growth to make an infection asymptomatic, 
(and untreated [3]) rather than symptomatic, is necessary to better understand the likelihood 
Figure 1. Hypothesised infection trajectories for sub-patent infections. An individual that has low-density asymptomatic 
infection on a given day can have several potential outcomes: s/he could continue to have long- (orange curve) or short-
lasting (yellow curve) low-density infection, with limited infectiousness to mosquitoes and never developing symptoms 
or seeking treatment. The same individual could also be very recently infected and in the pre-symptomatic stage (dark 
blue line), or experience a slower increase in parasite density to a level where symptoms develop (light blue line). Another 
possible outcome is that parasitaemia fluctuates between detectable and undetectable levels by microscopy (green line). 
Any of these scenarios could be perturbed by re-infection, which could result in either continued asymptomatic infection 
or development of symptoms. RDT, rapid diagnostic test; NAAT, nucleic acid amplification techniques.
Understanding the Importance of Asymptomatic and Low-Density Infections…
http://dx.doi.org/10.5772/intechopen.77293
131
of transmission from these infections. This will allow an assessment of whether specific indi-
viduals with asymptomatic infections need to be targeted and, if so, how this might be done, 
for example by enhanced coverage efforts or more sensitive infection detection tools targeted 
at those individuals who have a higher probability of being chronically infected.
In Sections 2 and 3, we consider factors that influence the establishment of asymptomatic infec-
tions and their parasite and gametocyte carriage levels. Specifically, we discuss how different 
factors might relate to the different archetypes of parasite dynamics described in Figure 1: 
chronic infections with fluctuating patent and sub-patent levels; chronic sub-patent infections; 
clinical episodes with short incubation period; clinical episodes with long incubation period; 
and short asymptomatic infections. Additionally, we discuss how blood sampling for parasite 
detection can influence estimates of prevalence of sub-microscopic infections. In Section 4, we 
use malariotherapy data and validated mathematical models to assess the benefits of targeting 
the asymptomatic reservoir of parasites.
2. Human factors influencing the duration of infection
The development of asymptomatic and low-density infections is intimately related to an indi-
vidual’s tolerance to parasites [12]. Several host characteristics have been linked to differential 
clinical expression of malaria infection, as well as to modulation of parasite levels, including 
genetic factors [13], acquired immunity [14, 15], co-infections with non-falciparum malaria 
parasites [16], iron status [17], among others. In this section, we discuss two widely prevalent 
factors that are likely to influence the frequencies of asymptomatic and low-density infec-
tions in various settings: haemoglobinopathies, which are genetically determined and conse-
quently whose effects on parasites might remain unchanged with decreases in transmission, 
and acquired immunity, that varies with cumulative exposure to parasites and will wane as 
exposure drops or ceases.
Both haemoglobin S (HbS) and haemoglobin C (HbC) mutations are protective against clin-
ical malaria [18], and evidence from a longitudinal study performed in Uganda [19] sug-
gests that HbS reduces progression of infection to disease. This protective effect suggests 
that these mutations are associated with chronic infections or clinical episodes with delayed 
onset (Figure 1; light blue, green or orange line). Data also suggest that the parasite densities 
observed in individuals with sickle cell trait [20] are lower compared to densities in HbAA 
individuals and thus presumably more likely to be sub-patent and not necessarily detected 
in population surveys. Given the high prevalence of haemoglobinopathies in many malaria 
endemic countries, particularly those in Africa for HbS [21, 22], and the potential for carriage 
of sub-patent infections, the contribution of this group of individuals to the transmission res-
ervoir should be considered. Determining how often parasite densities in heterozygous indi-
viduals are below the lower limit of detection of standard diagnostics would be informative. 
This is particularly relevant as haemoglobinopathies have been associated with increased 
gametocyte positivity and duration of gametocyte carriage [19, 23–25], which could amplify 
the infectivity of asymptomatic individuals with these mutations. Unlike naturally acquired 
immunity, these genetic traits will persist for several generations even after reductions in 
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malaria transmission and they have the potential to influence transmission phenotypes in the 
whole spectrum of endemicities, including in areas approaching malaria elimination.
Another cause of variation in the risk of symptoms and in parasite burden is acquired immu-
nity against asexual blood stage parasites, which develops with cumulative exposure and con-
sequently age. Asymptomatic adults have lower parasitaemias compared to children [4], and a 
higher proportion of their infections are sub-patent [26]. Adults are also less likely to develop 
symptoms, especially in highly endemic areas, and when they do, the parasite densities asso-
ciated with fever are on average lower than the corresponding densities in children [27]. On 
the other hand, estimates based on clone-specific carriage show that in highly endemic areas, 
asymptomatic infection duration is higher in schoolchildren compared to adults [8] though the 
differential detectability of clones may affect observations. Together, these studies suggest that 
infections in adults most commonly correspond to the archetype parasite dynamics of short 
duration asymptomatic infection or chronic infections with sub-patent carriage (Figure 1, yel-
low and orange lines). In settings where transmission intensity approaches elimination levels, 
depending on how fast transmission decreases, acquired immunity in adults would still be 
effective against parasitaemia and symptoms, while in young children with limited cumula-
tive exposure to falciparum parasites, this might not be the case. In this scenario, the epide-
miological differences between these demographic groups could be enhanced. Interestingly, 
in an area of Papua New Guinea with recent declines in transmission, reductions in parasite 
prevalence have been associated with an increase in the proportion of infections that are sub-
patent [28], indicative, perhaps of persisting immune responses that control parasitaemia in a 
setting where the incidence of super infection is reduced.
Short-term changes in immunity might also be relevant. For example, recent malaria infection 
might modulate immune responses to subsequent infections [29], which suggests that dynam-
ics of parasitaemia might differ at the start versus peak of transmission season, and so might 
the proportion of infected individuals that remain asymptomatic. Indeed, several epidemio-
logical studies using different methodologies have shown that the risk of clinical symptoms 
during infection varies during a transmission season: Mueller and colleagues [30] observed 
that after adjusting for the incidence of new infections, defined by molecular identification of 
individual clones, the risk of clinical malaria per infection was higher at the beginning of the 
transmission season. In Mali, the ratio of asymptomatic to symptomatic infections was higher 
during the low transmission season compared to the rainy season [31]. Whether this is due 
to modulation of host immune responses or to changes in parasite phenotype, it may result 
in longer infections at the end of the transmission season that would be advantageous for fal-
ciparum parasite populations to persist over the often long dry seasons. Furthermore, short-
term immunological changes might also directly affect infectivity of asymptomatic infections: 
in Burkina Faso, experimental mosquito infections indicate that short-lived immunity that 
reduces transmission is boosted after season-long exposure to parasites [32].
Of note, high-density infections in the absence of symptoms have been described, in par-
ticular in young children [3, 33, 34]. The relevance of these infections to transmission is 
unknown, although it could be anticipated that unless commitment to sexual development 
is reduced, these infections will produce high numbers of gametocytes and be potentially 
highly infectious.
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3. Parasite factors associated with infection duration
After inoculation of sporozoites and the subsequent release of merozoites from the liver, there is 
a period of time when parasites are present in the blood at concentrations undetectable by con-
ventional diagnostics. In many individuals, parasites then multiply to reach detectable densi-
ties, however in other individuals, parasites may remain at low densities that are undetectable. 
Human challenge studies on non-immune individuals in which parasites are monitored both 
by molecular methods and by microscopy have estimated that infections are detectable by PCR 
an average of 3.7 days (range 2–4 days) [35] or 3.1 days (range 0–4) [36] before being detectable 
by microscopy. Controlled human infections also suggest that the parasite stages that precede 
blood invasion might influence asexual blood stage dynamics. For example, Churcher and col-
leagues [37] observed that the inoculum size (the estimated number of sporozoites injected by 
infected Anopheles mosquitoes) influences the time it takes for infections to become patent: indi-
viduals receiving five bites from mosquitoes with more than 1000 sporozoites have detectable 
parasitaemia at least 2 days earlier than those volunteers infected by mosquitoes with 11–101 
sporozoites. Quantification of sporozoite counts in wild-caught mosquitoes is necessary to con-
firm the relevance of this finding in natural settings. In Papua New Guinea, it was estimated 
that infected malaria vectors had on average (geometric mean) 4000 sporozoites [38], which is of 
the same order of magnitude as sporozoite counts in mosquitoes used in controlled infections.
Microscopy has limited sensitivity to quantify low parasite densities and this will affect its utility 
for studying any chronicity in infection dynamics. Histidine rich protein 2 (HRP-2), a protein the 
parasite secretes in the plasma, is considered to be a more accurate measure of total falciparum para-
site burden [39], however, this measure does not distinguish between monoclonal and multiclonal 
infections. Molecular tools are more sensitive and allow discrimination of different parasite geno-
types. They have been used to assess the effects of super-infection and exposure to different parasite 
clones on clinical malaria risk. A study that involved daily blood sampling of children with ini-
tially asymptomatic infections [40] suggests that development of symptoms is often associated with 
appearance of a new parasite strain in the blood and increases in parasite levels. Correspondingly, 
recent data from Papua New Guinea [16] showed that incidence of infections by new clones cor-
relates with clinical malaria risk. This indicates that clinical malaria is often associated with new 
infection, presumably by a parasite clone with a previously unencountered antigenic profile.
Consistent with this, genetic analysis of malaria parasite populations in Zambia [41] found 
that in some settings individuals with symptomatic infections had different parasite strains 
compared to asymptomatic individuals. One hypothesis for this is that symptomatic infec-
tions originated from imported or recently introduced strains and that immunity to these 
strains is insufficient. This indicates that the rate of importation may play a role in the propor-
tion of infections that are asymptomatic and symptomatic, especially in areas approaching 
elimination. An infection with a clone to which immunity has been acquired might lead to 
infections with shorter duration (e.g., Figure 1, yellow line).
3.1. Gametocytes in asymptomatic infections
Gametocytes derive from a small percentage of asexual parasites that commit to sexual 
development; therefore, asymptomatic infections with low asexual levels may also have low 
Towards Malaria Elimination - A Leap Forward134
gametocyte densities. Data from epidemiological studies confirm that most asymptomatic 
infections with patent or sub-patent asexual stage parasite levels have sub-patent gametocy-
taemia [42], only detectable by RNA-based molecular methods. However, a few asymptom-
atic individuals with low-density infections have relatively high gametocyte densities, which 
could be related to symptomless fluctuations in parasitaemia that result in higher gametocy-
taemia a few days later. The rate of commitment of asexually replicating parasites to sexual 
development is another factor that influences gametocyte levels in malaria infections. Adults, 
who on average carry lower asexual stage parasite densities, have a higher sexual to asexual 
density ratio [43]. This could be related to an unequal increase in clearance rates of asexual 
and sexual parasites with age, or potentially to changes in commitment to gametocytogenesis 
[43]. Consistent with the latter, parasite investment in transmission stages has been shown to 
vary in areas with different transmission levels, being higher in settings with lower endemic-
ity. Recent data suggest that parasite variations in commitment to gametocytes are epigeneti-
cally imprinted and higher in parasites in lower endemicity settings [44].
As articulated above, the importance of asymptomatic infections for malaria transmission 
does not lie in their average sexual stage parasite densities but in the durations of gameto-
cyte carriage and infectiousness over time. A mathematical model [45] fitted to both asexual 
parasite and gametocyte malariotherapy data estimated infectivity over the course of an 
infection based on gametocyte density data. This analysis concluded that the majority of 
infectivity was usually concentrated early in infection, although some patients were signifi-
cantly infectious later on. However, in this model, it was assumed relatively low infectiv-
ity of low gametocyte densities compared with other analyses [46]. While these data are 
extremely detailed, it is not known whether these dynamics are similar to those in naturally 
infected individuals who have immunity. Furthermore, specific P. falciparum strains were 
selected for malariotherapy because they were ‘benign’ and may not exhibit the same behav-
iour in terms of parasite multiplication rates and gametocyte commitment as parasites in 
endemic areas.
Although asymptomatic infections do not prompt treatment-seeking behaviour, during com-
munity mass treatment campaigns that involve treatment regardless of symptomatology 
(e.g., mass drug administration (MDA) or mass screening and treatment), these infections 
are cleared with antimalarials. In a meta-analysis of trials with gametocyte density data [47], 
the combinations artesunate-mefloquine and artemether-lumefantrine were more effective 
in preventing the appearance of gametocytes and in clearing existing sexual stage parasites 
compared to dihydroartemisinin-piperaquine. The choice of drugs to be used during con-
trol interventions thus may be important to limit residual transmission from these infections. 
In Section 4, we discuss the impact of different interventions that target asymptomatic and 
symptomatic infections.
3.2. Underestimations of parasitaemia linked to sampling
Two variables linked to blood sampling for parasite detection can influence prevalence and 
density estimates: volume and timing. Even sensitive molecular assays will not detect low 
parasite densities in samples if nucleic acids are isolated from small blood volumes. High-
volume PCR has been used in epidemiological studies in Southeast Asia to circumvent 
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this problem and less than 30% of all falciparum infections are estimated to be missed by 
this method [48]. The timing of blood sampling in parasitological surveys might also affect 
parasite detection and quantification because asexual falciparum parasites do not circulate 
continuously; sequestration of falciparum schizonts starts 12-18 hours after merozoite inva-
sion and during this period they might not be detectable. An intensive longitudinal study in 
Tanzania showed that periodic changes in parasite densities are common. The periodicity 
of clone-specific detectability indicates that in natural infections, synchronised sequestration 
of clonal parasite populations occurs [49]. A study [50] that collected samples on two con-
secutive days found a prevalence disparity of approximately 25% between the two samples. 
Periodic changes in parasite levels could have a direct impact on the selection of diagnostics, 
for example by favouring assays that detect more persistent markers, such as HRP-2.
The detection of either asexual or sexual stage parasites is sufficient to establish the diagno-
sis of infection. Although gametocytes are not known to periodically sequester, there is evi-
dence of periodic variation in gametocyte levels [51] in peripheral blood. For several decades 
now [52], accumulation of mature gametocytes in the skin [53] has been hypothesised as a 
possible mechanism of transmission enhancement. If confirmed, this would imply that sub-
patent gametocytaemias in peripheral blood might be associated with higher-than-expected 
infectivity.
4. Contribution of low-density asymptomatic infections to 
transmission
In the previous sections, we discussed factors influencing the duration and average density 
of individual infections. In this section, our goal is to understand the significance and con-
tribution of low-density asymptomatic infections to local transmission. This question is par-
ticularly important in areas where control efforts have pushed transmission towards near 
elimination levels – in this case it has been hypothesised that chronic low density asymptom-
atic infections could maintain local transmission.
4.1. Should we detect and treat low-density asymptomatic infections?
Since identifying the reservoir of low-density infections, there has been interest in develop-
ing more sensitive rapid diagnostics in order to detect and treat these infections. However, 
the benefit of treating such infections, both at the individual level and in terms of preventing 
onward transmission to others, remains unclear. The impact of treating a low-density infection 
depends not only on its current infectiousness to mosquitoes, but the future course of infection 
and infectiousness that is prevented (Figures 1 and 2). If low-density infections most com-
monly represent the tail end of an infection, which will clear rapidly without treatment, then 
the benefit of treatment would be small (Figure 2, yellow bar). However, if such infections 
commonly become chronic and lead to future periods of higher parasite densities, infectious-
ness, and possibly also symptoms, the benefit of treating such infections would be greater 
(Figure 2, green and light blue bars). Consistent with this second scenario, longitudinal data 
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from Vietnam suggest that chronic sub-patent infections can lead to high parasitaemias, 5–6 
orders of magnitude higher [11].
The relative proportions of low density infections which go on to rapidly clear versus those 
which become higher density infections are unknown and likely depends on many of the 
factors highlighted in Sections 2 and 3, such as age, immunity and host genetics. Studying 
variations in detectability over the course of a single naturally acquired infection is difficult 
for a few reasons: (i) super- and co-infections: in high transmission settings, most individuals 
are infected with more than one parasite clone [54] and standard techniques do not indicate 
the density of each parasite genotype (therefore the density of older versus newer infections 
cannot be distinguished); (ii) even using molecular methods, parasite densities often fluctu-
ate below detection limits before the end of an infection and it is difficult to distinguish this 
from clearance of infection; (iii) long follow up is needed: even in endemic areas where indi-
viduals have immunity, specific parasite genotypes have been shown to persist for more than 
6 months [55]. Here, we use a simple modelling framework to explore how the duration and 
infectiousness of an infection affect the impact of different intervention strategies.
4.2. Model framework
Four archetypal parasite density trajectories are identified from the malaria therapy data [57, 58] 
to represent broadly four potential outcomes of a new infection (Figure 3): (1) initially symptom-
atic before becoming asymptomatic and fluctuating between patent and sub-patent levels for a 
long time (~300 days); (2) initially symptomatic before becoming asymptomatic and fluctuating 
Figure 2. Estimated infectiousness to mosquitoes over course of infection and cumulative relative contribution to onwards 
infectiousness for each type of infection. The infectiousness of each parasite density trajectory from Figure 1 is estimated 
by assuming that individuals with very high parasite densities (associated with being febrile) are three times as infectious 
as individuals with microscopy-detectable asymptomatic infection, who are then in turn three times as infectious as 
individuals with sub-microscopic asymptomatic infection [32, 56]. The cumulative infectivity of an individual is simply 
the area under the infectiousness curve (left panel). This area under the curve of each type of infection is compared in 
the right panel.
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between patent and sub-patent levels for a short time (~120 days); (3) always asymptomatic and 
fluctuating between patent and sub-patent densities for a long time (~300 days); and (4) always 
asymptomatic and fluctuating between patent and sub-patent for a short time (~90 days). Note 
how these relate to the hypothesised profiles in Figure 1.
An age-structured population of individuals is simulated whereby individuals have a daily 
probability of acquiring a new infection. Upon being infected, an individual’s probability of 
developing symptoms is based on their age and the intensity of transmission (fitted estimates 
taken from [56]) (Table 1). In a single simulation, infections are assumed to be either all long 
(300 days) or all short (120 or 90 days). Infected individuals will follow one of the parasite den-
sity trajectories shown in Figure 3 unless they are treated or re-infected. Febrile individuals have 
a 50% probability of receiving treatment. Treated individuals are assumed to clear their asexual 
parasites after being febrile for 3 days, they then become non-infectious after 6 days. These indi-
viduals are also assumed to be protected from reinfection for 14 days after treatment.
The model is simulated with either high transmission (20% slide prevalence) or low trans-
mission (5% slide prevalence) and the daily probability of infection is fitted to achieve these 
prevalence levels. Infected individuals can be reinfected (unless they received treatment in the 
Figure 3. Parasite density trajectories from four infected individuals. The arrows represent the estimated time to clear 
infection (assuming a period of sub-patent infection after the last patent day of infection). The upper panel shows two 
symptomatic patients (red points indicate the days on which the patients were febrile) and the lower panel shows 
asymptomatic patients. The horizontal dotted line indicates the limit of detection of field microscopy (100 parasites/μl).
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last 14 days) at any time and will start at the beginning of a new parasite density trajectory 
selected based on their age-specific probability of developing symptoms. The impact of two 
interventions is simulated: increasing treatment coverage among febrile individuals to 90% 
or delivering a single round of MDA to a random 80% of the population. The effect of each 
intervention is assessed by calculating the percentage reduction in the combined onwards 
infectiousness of the whole population in the following year, which depends on whether they 
are in a patent and symptomatic, patent and asymptomatic or sub-patent state. Parasite den-
sity is translated to infectiousness according to assumptions described in Figure 2. After an 
intervention the infection risk is reduced proportionally with the reduction in the proportion 
of the population that are infected to account for the population-level impact of these inter-
ventions on transmission.
MDA is predicted to be more effective at reducing the infectious reservoir than increasing treat-
ment coverage among febrile individuals in low transmission settings with both short and long 
infection durations and high transmission settings with long infection durations only (Figure 
4). In these scenarios the rebound of infection is slow, meaning over the course of a year, MDA 
prevents a higher number of infected/infectious days than increasing treatment coverage of 
febrile individuals. In high transmission settings with a short duration of infection, a higher 
force of infection is needed to achieve a given prevalence. Therefore, the effect of any interven-
tion is reduced because the population become reinfected quicker. In this scenario, increas-
ing treatment coverage is more effective because it is a sustained intervention. It is important 
to note that the outcome metric considered here is the reduction in the infectious reservoir—
increasing treatment coverage is likely to always have the greatest impact on reducing malaria 
morbidity and mortality in all transmission scenarios. The model simply illustrates how our 
uncertainties about the duration of untreated infection affect estimates of intervention impact.
5. Conclusions
Since asymptomatically infected individuals do not actively seek antimalarial treatment, their 
infections may last longer than symptomatic episodes. In this chapter, we discussed human 
and parasite factors that influence the dynamics of parasitaemia and the duration of game-
tocyte circulation in these infections. These factors result in a range of infection profiles, the 
relative combinations of which in a population will define not only the composition of the 
infectious reservoir but the likelihood of success of intervention measures. For example, our 
calculations suggest that MDA is most effective if infections have long durations. In a high 
transmission setting, MDA might have been expected to be more effective than increasing 
Age range (in years)
0–5 5–15 15+
High transmission (20% slide prevalence) 66% 52% 38%
Low transmission (5% slide prevalence) 78% 70% 59%
Table 1. Probability of developing symptoms upon being successfully inoculated (estimates from [56]).
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treatment coverage, because higher immunity reduces the probability of developing symp-
toms and the proportion of infections getting treated. However, when transmission is high, 
the reduction in prevalence after an MDA is temporary, due to the drug half-life and imper-
fect coverage levels, and individuals are likely to become reinfected quickly, therefore in the 
Figure 4. Simulated impact of increasing treatment coverage or mass drug administration (MDA) on the proportion of 
mosquitoes infected by a population: influence of transmission setting and infection duration. The grey lines represent 
continuing 50% treatment coverage and no MDA, and the blue and red lines as shown in the legend.
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absence of repeated rounds of MDA, increasing treatment coverage may in fact be more effec-
tive in the long term (Figure 4). However, the model assumes no seasonality, when in reality 
many malaria endemic regions transmission is highly seasonal; this could underestimate the 
impact of MDA. As discussed above, seasonal changes in infection duration represent another 
aspect of the epidemiology of asymptomatic infections that could be explored to target inter-
ventions. Indeed, where transmission is seasonal, infections persisting during the dry season 
correspond to long-term asymptomatic carriage since incidence of new infections is thought 
to be negligible. This means that during this period, infections are likely to be missed by pas-
sive surveillance, while active approaches, such as MDA, might be more efficacious.
Determining the optimal control strategy, and moreover, whether asymptomatic/sub-patent 
infections actually need to be identified and treated, will require careful analysis of local epi-
demiological data. The three key metrics that need to be determined are: (1) the proportion 
of individuals that develop symptoms and seek treatment, (2) the distribution of durations of 
asymptomatic infections, and (3) the relative infectivity of different infections. These factors are 
in turn driven by the complex interplay of host immunological factors, such as strain-specific 
immunity, intrinsic parasite growth factors and population characteristics (e.g. prevalence 
of HbAA versus HbAS, variation in demographic risk within a community). The relative high 
prevalence of asymptomatic and low-density infections in areas with low transmission and high 
treatment coverage might indicate that either these infections are contributing towards transmis-
sion and enabling malaria to persist or that they reflect the tail end of infections with transmission 
maintained by the few highly infectious symptomatic cases. This will vary in different settings 
and whilst the rapid identification and treatment of symptomatic malaria infections remains key 
to all control approaches, a better understanding of the nature of asymptomatic infections will 
determine if and what additional measures are required for malaria elimination.
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